This finding highlights the potential of molecules that reactivate mutant p53 as targeted, tumor-suppressive strategies for treating p53-mutant cancers, with the added benefit of enhancing treatment efficacy by inhibiting HMGA1 secretion. This evidence concerns the gene TP53 and cancer.